MAXOLON

This brand name is authorized in Australia, Ireland, New Zealand, United Kingdom, South Africa

Active ingredients

The drug MAXOLON contains one active pharmaceutical ingredient (API):

1 Metoclopramide UNII W1792A2RVD - METOCLOPRAMIDE HYDROCHLORIDE

The action of metoclopramide is closely associated with parasympathetic nervous control of the upper gastro-intestinal tract where it has the effect of encouraging normal peristaltic action. This provides for a fundamental approach to the control of those conditions where disturbed gastrointestinal motility is a common underlying factor. Read about Metoclopramide

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
MAXOLON Solution for injection	Medicines & Healthcare Products Regulatory Agency (GB)	MPI, EU: SmPC
MAXOLON Tablet	Medicines & Healthcare Products Regulatory Agency (GB)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
A03FA01	Metoclopramide	A Alimentary tract and metabolism → A03 Drugs for functional gastrointestinal disorders → A03F Propulsives → A03FA Propulsives
Discover more medicines within A03FA01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: AU	Pharmaceutical Benefits Scheme	Identifier(s): 10762K, 1206L, 1207M, 12507G, 3476Y, 5151D, 5153F
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 15706
Country: IE	Health Products Regulatory Authority	Identifier(s): 32374, 32921, 70246
Country: NZ	Medicines and Medical Devices Safety Authority	Identifier(s): 668
Country: ZA	Health Products Regulatory Authority	Identifier(s): C/5.7.2/1014, C/5.7.2/918, C/5.7.2/920, H/5.7.2/200, H/5.7.2/201